LONG-TERM DRUG SURVIVAL OF ETANERCEPT VS OTHER TNF INHIBITOR THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Emery, P. [1 ]
Vlahos, B. [2 ]
Szczypa, P. [3 ]
Thakur, M. [4 ]
Jones, H. E. [2 ]
Woolcott, J. [2 ]
Estrella, P. V. Santos [2 ]
Gibofsky, A. [5 ]
Rolland, C. [6 ]
Citera, G. [7 ]
Marshall, L. [2 ]
机构：
[1] Leeds Inst Rheumat & Musculoskeletal Med, Leeds Musculoskeletal Biomed Res Ctr LTHT, Leeds, W Yorkshire, England
[2] Pfizer, Collegeville, PA USA
[3] Pfizer Ltd, Walton Oaks, GA USA
[4] Pfizer, Sandwich, Kent, England
[5] Weill Med Coll, New York, NY USA
[6] Envis Pharma Grp, Horsham, W Sussex, England
[7] Consultorios Reumatol, Buenos Aires, DF, Argentina
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2504
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0460
引用
收藏
页码：1391 / 1392
页数：3
相关论文
共 50 条
  • [21] Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers
    Arora, Anamika
    Mahajan, Anadi
    Spurden, Dean
    Boyd, Helen
    Porter, Duncan
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2013, 2013
  • [22] Adopting Low-Dose Etanercept Strategy in the Long-Term Management of Rheumatoid Arthritis Patients
    Raffeiner, Bernd
    Botsios, Costantino
    Todesco, Silvano
    Bernardi, Livio
    Ometto, Francesca
    Vezzari, Cristiana
    Sfriso, Paolo
    Punzi, Leonardo
    CLINICAL DRUG INVESTIGATION, 2013, 33 : S128 - S130
  • [23] Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis
    van den Reek, J. M. P. A.
    van Lumig, P. P. M.
    Driessen, R. J. B.
    van de Kerkhof, P. C. M.
    Seyger, M. M. B.
    Kievit, W.
    de Jong, E. M. G. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 415 - 424
  • [24] Long-term drug therapy of rheumatoid arthritis and remission
    Pyai, L
    Pyai, S
    TERAPEVTICHESKII ARKHIV, 2000, 72 (05) : 21 - 25
  • [25] Long-term changes in the quality of life of patients with rheumatoid arthritis treated with biological therapies
    Ortega-Valin, Luis
    Mayorga-Bajo, Isabel
    Prieto-Fernandez, Carolina
    del Pozo-Ruiz, Javier
    Gutierrez-Gutierrez, Esperanza
    Perez-Sandoval, Trinidad
    REUMATOLOGIA CLINICA, 2018, 14 (04): : 191 - 195
  • [26] Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept
    Lorenzo Cavagna
    Vincenzo Sepe
    Francesca Bobbio-Pallavicini
    Filippo Mangione
    Roberto Caporali
    Carlomaurizio Montecucco
    International Urology and Nephrology, 2011, 43 : 909 - 912
  • [27] Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept
    Cavagna, Lorenzo
    Sepe, Vincenzo
    Bobbio-Pallavicini, Francesca
    Mangione, Filippo
    Caporali, Roberto
    Montecucco, Carlomaurizio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2011, 43 (03) : 909 - 912
  • [28] The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis
    Giannini, E. H.
    Llowite, N. T.
    Lovell, D. J.
    Wallace, C. A.
    Rabinovich, C. E.
    Reiff, A. O.
    Higgins, G.
    Chon, Y.
    Lin, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 550 - 550
  • [29] EXPLORING LONG-TERM DRUG EFFECTIVENESS AND DRUG SURVIVAL FOR RITUXIMAB REFERENCE DRUG IN TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ORDINARY OUTPATIENT CLINIC
    Losinska, K.
    Wilk, M.
    Pripp, A. H.
    Korkosz, M.
    Haugeberg, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1136
  • [30] Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate
    l'Ami, M. J.
    Kneepkens, E. L.
    Nurmohamed, M. T.
    Krieckaert, C. L. M.
    Visman, I. M.
    Wolbink, G. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (03) : 431 - 437
12345